
The best Fourth of July mattress sales: Save up to 35% on Saatva, DearFoam, Helix and more
You can browse, compare and purchase your mattress without the need to visit multiple physical stores. If you're not sure where to start, jump down to our FAQs where we go over some of the most frequently asked questions that come up when you buy a mattress online.
Keep scrolling to see our best mattresses for side sleepers, stomach sleepers, back sleepers, combination sleepers, back pain, heavy sleepers and couples.
Side sleepers should look for a mattress that offers pressure relief and pick something in the medium-soft to medium-firm range. Lighter individuals might prefer something softer, while heavier side sleepers might need a bit more support to prevent sinking into the mattress.
Original price: $1,598
Nectar's flagship memory foam mattress is a good fit for a side sleeper because of the pressure-relieving memory foam and medium-firm feel. The Nectar Classic's gel-infused memory foam comfort layer excels at conforming closely to the body's curves. This allows these pressure points to sink in just enough, distributing weight evenly and preventing painful pressure buildup.
Grab your mattress on sale this Fourth of July. Nectar offers a 365-night sleep trial to test out the mattress.
Original price: $799
The DreamFoam Hybrid by Brooklyn Bedding features individually-wrapped coils for support and breathability, topped with a cooling panel and gel memory foam for temperature regulation and comfort. It's a great option for a side sleeper because it offers a good balance of contouring comfort and responsive support, with better airflow than all-foam options for cooler sleep.
Fox News readers can get 30% off using the coupon code FOX30 at checkout, which is valid from June 27 to July 4. The mattress is shipped in a box and with a 120-night comfort trial to see if the mattress is right for you.
Original price: $1,332
The Helix Midnight is a good mattress for those that prefer a medium-firm feel. The Midnight's hybrid construction (foam and coils) provides a balance of comfort and support. The zoned support helps distribute pressure and provides adequate spinal alignment.
Fox News readers can get 27% off using the coupon code FOX27 at checkout, which is valid until July 31. Helix Sleep offers a 100-night sleep trial to test out the mattress.
Original price: $3,699
The Leesa Reserve Hybrid features a 14-inch profile and a luxurious combination of high-density foam and individually-wrapped coils. It has a plush, supportive feel, with medium firmness levels that is perfect for supporting side sleepers.
The mattress is shipped in two boxes. Customers have 100 nights to sleep on their Leesa mattress to see if it's a good fit.
Stomach sleepers should look for a firm mattress to maintain proper spinal alignment and prevent the hips from sinking too deeply.
Original price: $1,699
The Layla Hybrid Mattress is designed to be flippable, offering two different firmness levels: a softer side and a firmer side. For most stomach sleepers, the firm side of the Layla Hybrid Mattress will be the preferred option as it keeps the hips from sinking too deeply into the mattress.
Layla offers a 120-night sleep trial for their mattresses. Get an extra $150 off on all Layla mattresses using the code FOX150 and purchases of more than $100 get an additional $20 off using the code FOX20. Plus, all mattress purchases come with two of Layla's award-winning memory foam pillows.
Original price: $1,332
The Leesa Original Foam Mattress is designed to provide a balance of comfort, support and pressure relief that stomach sleepers need. The mattress is made entirely of foam layers and has a medium-firm feel, rated around a 5 to 7 out of 10 on the firmness scale.
You can add white glove delivery for professional unboxing, assembly and hauling away old items.
Original Price: $1,332
The Plank Firm mattress by Brooklyn Bedding is for people who want the firmest feel for their mattress. It's a flippable, all-foam mattress with two distinct firmness options on each side. This is the firmest all-foam mattress currently on the market.
Fox News readers can save 30% using the code FOX30 from June 27 to July 4. The mattress has a 120-night comfort trial to see if it is the right fit.
Back sleepers should choose a mattress that provides a balance of support and comfort to maintain the natural curvature of the spine.
Original price: $2,265
Brooklyn Bedding's Aurora Luxe Cooling mattress coil system offers back sleepers excellent foundational support that prevents the midsection from sinking too deeply. The coils respond independently to pressure and give targeted support where needed. The Aurora Luxe comes in soft, medium and firm options, so you can choose the firmness level that is best for you.
Fox News readers can get 30% off using the coupon code FOX30 at checkout, which is valid from June 27 to July 4. The mattress is shipped in a box and with a 120-night comfort trial.
Original price:$1,383
Awara's Natural Luxury Hybrid mattress is firm and a good choice for back sleepers because of its spinal alignment. The firm support core from the individually wrapped coils, combined with the responsive buoyancy of the natural latex, provides an ideal surface for keeping the spine in a neutral position.
This mattress is on sale for the Fourth of July weekend. Awara offers a 365-night sleep trial to test out the mattress.
Combination sleepers will do better with a hybrid mattress. A hybrid mattress combines the best of two worlds to offer a balanced sleeping experience that provides both strong support and comfortable pressure relief.
Original price: $2,127
The Nolah Evolution mattress is Nolah Sleep's best-selling mattress. This luxury hybrid mattress is a favorite because it delivers a combination of pressure-relieving foam and supportive coils, particularly beneficial for side sleepers. It features a 15-inch thickness, a plush pillow top and active cooling technology, along with zoned support for targeted comfort.
Nolah mattresses have a 120-night trial period with a 30-night break-in period. You can also buy the Nolah Evolution on Wayfair.
Original price: $2,398.66
The Helix Midnight Luxe is a good option for combination sleepers, especially those who primarily alternate between side and back sleeping. The mattress has a medium feel that offers enough softness for pressure relief when on your side, but enough support to keep your spine aligned when you roll onto your back. The hybrid construction that uses foam layers with individually wrapped coils.
Fox News readers can get 27% off using the coupon code FOX27 at checkout, which is valid through July 31. You can also buy this mattress on Amazon. Helix Sleep offers a 100-night sleep trial for their mattresses, during which time you can return them for a full refund if you are not satisfied.
Back pain is a major reason Americans lose sleep at night, and a bad mattress only exacerbates the situation. A good mattress for back pain focuses on alignment while also providing the right level of support, firmness and comfort.
Original price: $2,849
PlushBeds Botanical Bliss Organic Latex Mattress provides a combination of resilient support for optimal spinal alignment and conforming pressure relief that is essential for alleviating and preventing various types of back pain. The latex makes this mattress buoyant and responsive, which is critical in keeping your hips from sagging and your lower back will be adequately supported.
Save $1,500 on all PlushBeds mattresses until July 4th. PlushBeds includes a 100-night trial period for all of its mattresses.
Original price: $2,427
What we love: Its zoned support coils and pressure-relieving foams help maintain spinal alignment and alleviate pressure points.
What to be aware of: Lightweight sleepers might find the Medium or Firm options too firm for optimal pressure relief.
The Bear Elite Hybrid is a good option for back pain, particularly for back sleepers of various weights. The Bear Elite Hybrid comes in soft, medium and firm options. This allows you to choose a firmness level that best supports your spine and alleviates pressure points.
You can save 35% using the coupon code FOX35 through July 7. The Bear mattress sleep trial is a 120-night period, after which you can return the mattress at no cost if you don't like it.
Heavier sleepers should prioritize durability and robust construction with a medium-firm to firm mattress. Hybrid mattresses are a good choice for heavier sleepers because they combine the robust support and durability of innerspring coils with the pressure relief and contouring of foam comfort layers.
Original price: $1,599
The Titan Plus Luxe is the best deal for a luxury mattress option for those weighing more than 230 pounds who need robust support but also want a comfortable, medium-firm feel with good pressure relief.
Save 30% off with the coupon code FOX30 from June 27 to July 4. The mattress is shipped in a box and with a 120-night comfort trial to see if it is right for you. You can also buy the Titan Plus Luxe on Amazon.
Original price: $599
What we love: The individually pocketed coils and foam layers work to absorb movement so you're less likely to be disturbed by a partner tossing and turning.
What to be aware of: The mattress may be too soft for stomach sleepers.
The EGOHOME Black 14-inch Hybrid Mattress has a medium-firm firmness level, ideal for heavier sleepers as it provides a good balance of support to prevent sinking and enough cushioning for comfort. The mattress also has good edge support, which is a key consideration because it will prevent the mattress from sagging at the sides, making it easier and safer to get in and out of bed and maximizing the usable sleep surface.
Save an extra 11% off with the coupon code FN11 valid until July 7. The mattress has a 100-night comfort trial to see if it is right for you.
When sharing a mattress, whether with a partner, child or pet, look for an option that will enhance comfort and minimize disturbances for both sleepers.
Original price: $1,598
The DreamCloud Premier is an all-memory foam mattress designed for pressure relief. This 13-inch mattress is made with a breathable CloudQuilt top. This mattress is a good choice if you are looking for motion isolation and is suitable for a range of sleeping preferences.
DreamCloud offers a 365-night sleep trial and if you are not happy with the mattress you can request a return and receive a full refund.
Original price: $1,016
Pick the Siena Premier Hybrid Mattress for its excellent motion isolation. This hybrid mattress uses individually-wrapped coils that move independently, which reduces motion transfer. Plus, the mattress features reinforced coils along the perimeter on all four sides for strong edge support, so couples can spread out and use the entire surface of the mattress.
Siena mattresses are on sale for the Fourth of July weekend, and come with a sleep trial of 180 nights.
Original price: $2,624
Latex mattresses feel similar to memory foam but feel firmer with less sinking in. This latex mattress from Birch by Helix is eco-friendly. The latex and organic cotton contribute to a cooler sleeping surface, which can be beneficial for couples who tend to overheat during the night.
Save 27% at Birch Helix using the coupon code FOX27 until July 6. You will also get two free eco-rest pillows with a mattress purchase. Birch by Helix offers a 100-night sleep trial for their mattresses.
For more deals, visit www.foxnews.com/deals
Buying a mattress online is convenient and can offer more benefits than visiting an actual showroom. To help out in your search, here are a few answers to the most commonly asked questions consumers have when buying a new mattress online.
Picking out the best mattress brand will depend entirely on your specific needs, preferences and budget. The brands featured in our guide consistently receive high ratings and are well-regarded for different reasons. Many of these mattress brands offer mattress quizzes that can help guide you to options based on your preferences.
How long your mattress lasts depends on the quality of the mattress and how you care for it. You will know it's time to replace your mattress if you see signs of visible sagging or deep body impressions. Another good indicator signaling that your mattress is likely to no longer provide adequate support is if you consistently wake up with back, neck, hip or shoulder pain that wasn't there before. An old mattress can accumulate dust mites, mold and allergens, leading to increased allergy symptoms.
Choosing the best mattress depends on individual needs and preferences. Side Sleepers generally do better with a softer to medium-firm mattress that contours to their body to relieve pressure on hips and shoulders and maintain spinal alignment. Back sleepers may prefer a medium to firm mattress that provides consistent support to keep the neck, shoulders and torso aligned. Stomach sleepers should opt for a firmer mattress to prevent their hips from sinking too far, which can lead to back pain.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Keysight Technologies Inc (KEYS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and AI ...
This article first appeared on GuruFocus. Revenue: $1.4 billion, up 11% year-over-year. Earnings Per Share (EPS): $1.72, exceeding guidance. Orders: Increased by 7% year-over-year. Gross Margin: 64%. Operating Expenses: $526 million. Operating Margin: 25%, up 60 basis points from last year. Net Income: $297 million. Communications Solutions Group Revenue: $940 million, up 11% year-over-year. Electronic Industrial Solutions Group Revenue: $412 million, up 11% year-over-year. Cash Flow from Operations: $322 million. Free Cash Flow: $291 million. Cash and Cash Equivalents: $2.636 billion. Share Repurchase: 300,000 shares at an average price of $164, totaling $50 million. Q4 Revenue Guidance: $1.370 billion to $1.390 billion. Q4 EPS Guidance: $1.79 to $1.85. Warning! GuruFocus has detected 6 Warning Signs with VVOS. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Keysight Technologies Inc (NYSE:KEYS) reported an 11% year-over-year increase in revenue to $1.4 billion, exceeding the high end of their guidance. Orders increased by 7% with growth across both the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The company saw strong growth in aerospace, defense, government, and general electronics, with stability in wireless and automotive sectors. Keysight Technologies Inc (NYSE:KEYS) is capitalizing on AI momentum, with significant investments in AI-related technologies and partnerships, such as with AMD for PCIe Gen 6 compliance validation. The company reported a gross margin of 64% and an operating margin of 25%, with earnings per share of $1.72, up 9% year over year. Negative Points The company is facing challenges with tariffs, which are expected to increase their tariff exposure by approximately $75 million annually. Despite strong performance, the automotive sector remains stable year over year, indicating potential challenges in achieving growth in this segment. The broader 6G commercialization is still years away, which may delay potential revenue from this technology. The company is experiencing headwinds in the semiconductor sector, despite robust demand for wafer test solutions. There are ongoing geopolitical and macroeconomic uncertainties that could impact future performance and market conditions. Q & A Highlights Q: Satish, on past calls, you characterized your expectation for a recovery in the end markets overall as gradual. I don't think I heard you use that word today. Can you help investors understand your view of the end markets now and to what extent it's better than you'd previously expected? A: Strong quarter, clearly, and we're feeling good about the funnel and customer activity despite the overhang from tariffs and geopolitical environment. Order growth has accelerated, and we're feeling slightly better than expected at the beginning of the year. However, not all end markets are up; AI and aerospace defense are strong, while automotive faces challenges. Q: Can you help us better understand what's supporting the revenue outlook into 4Q, given that orders were up high-single digits but the book-to-bill was just below 1? A: Some of this is due to the timing of big deals. We had a large system integration deal accepted on the last day of Q3, which elevated Q3 performance and pulled from Q4. We expect more normal sequential seasonality on the order front than on the revenue front due to the timing of these deals. Q: Neil, as we think about revenue growth and recovery, you mentioned a 5% to 7% top-line growth rate as a long-term model. Is that how we should think about fiscal '26? A: We started the year with a gradual recovery expectation and are now looking at revenue growth at the low end of that range. Things have unfolded slightly better, allowing us to raise expectations. We're bullish going into '26, with caution around tariffs and macroeconomic factors. Q: How do you respond to investors asking about the mix of AI's contribution to the Keysight story, particularly in wireline? A: We're well-positioned for the long-term AI opportunity. AI will contribute across multiple end markets over time. Wireline business is expected to finish strong due to AI demand. It's hard to isolate AI's impact as it involves entrenched ecosystems, but business with us is growing, driven by AI. Q: Can you outline where the tariffs are most substantial for you, and is the mitigation plan focused on moving production or pricing? A: We have a geographically diverse manufacturing footprint, with significant operations in Southeast Asia, the EU, Japan, and the US. Mitigation involves supply chain strategies, possibly shifting manufacturing, and passing costs to customers through price increases and surcharges. We expect to fully mitigate the April tariffs by Q1 and the August increase by the first half of FY26. Q: On aerospace and defense, should we see this market continue to accelerate, or is this a good level due to the time it takes for programs to get into place? A: The starting point for the year was slower, but demand has returned in the second half. Ongoing programs and backlog for prime contractors are robust, indicating a positive environment. The US situation is understood, and European spending could impact long-term growth. Aerospace and defense are steady value creators, though growth may not be as quick as commercial markets. Q: Could you touch on the moving parts around the incremental margin of 40% you talked about? A: The 40% incremental margin is the right long-term target. Tariffs impacted this year's ability to deliver, but once included in the baseline, we can achieve it with mid-single-digit growth. Stripping out tariff impact, we are overachieving the 40% incremental in recent quarters. Q: Can you provide thoughts on customer engagement timelines and when 6G might become a more meaningful revenue contributor? A: Recent 3GPP meetings reinforced industry alignment from 5G to 6G, which is positive for us. Customers are exploring 6G facets, building IP for eventual rollout. While years away from rollout, R&D activity will grow, and we're well-positioned to support this transition. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
19 minutes ago
- Yahoo
Evogene Ltd (EVGN) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ...
This article first appeared on GuruFocus. Total Revenue (H1 2025): $3.2 million, up from $2.3 million in H1 2024. Research and Development Expenses (H1 2025): $4.8 million, down from $6.5 million in H1 2024. Sales and Marketing Expenses (H1 2025): $800,000, down from $1.1 million in H1 2024. Total Operating Expenses (H1 2025): $7.7 million, down from $11.1 million in H1 2024. Cash and Short-term Bank Deposits (End of H1 2025): $11.7 million. Operating Loss (H1 2025): $6.1 million, down from $9.4 million in H1 2024. Net Loss (H1 2025): $7.7 million, down from $9.8 million in H1 2024. Cash Usage (Q2 2025): $2.4 million. Financing Income (H1 2025): $732,000, up from $373,000 in H1 2024. Loss from Operations Held for Sale, Net (H1 2025): $2.2 million, up from $0.8 million in H1 2024. Warning! GuruFocus has detected 6 Warning Signs with EVGN. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Evogene Ltd (NASDAQ:EVGN) reported an increase in total revenues for the first half of 2025 to approximately $3.2 million, up from $2.3 million in the first half of 2024, driven by strong seed sales from its subsidiary Casterra. The company executed a cost reduction plan, resulting in a significant decrease in operating expenses, with total operating expenses net for the first half of 2025 at approximately $7.7 million compared to $11.1 million in the same period last year. Evogene Ltd (NASDAQ:EVGN) completed the sale of Lavie Bio's assets and the MicroBoost AI for Ag tech-engine to ICL, generating significant cash flow and enhancing the company's financial position. The company is focusing on maximizing the value of its ChemPass AI platform, which has been strengthened by the completion of the GeneRator AI foundation model developed in collaboration with Google Cloud. Evogene Ltd (NASDAQ:EVGN) successfully raised $4.4 million through its ATM facility, providing a solid financial foundation and operational runway of approximately 18 months. Negative Points Evogene Ltd (NASDAQ:EVGN) is undergoing a strategic shift, which includes significant organizational changes and workforce reductions, potentially impacting employee morale and operational stability. The company reported a net loss for the first half of 2025 of approximately $7.7 million, although this was a decrease from the $9.8 million loss in the same period last year. There is uncertainty regarding the commercialization of Casterra's castor seed inventory, as the company is exploring options to sell seeds directly or grow and sell grain. The ongoing geopolitical situation in Israel, including the conflict with Hamas and Hezbollah, poses risks and uncertainties that could affect the company's operations and financial performance. Evogene Ltd (NASDAQ:EVGN) faces challenges in achieving peak sales and establishing new partnerships, particularly in the pharma and agriculture sectors, which are crucial for future growth. Q & A Highlights Q: How much castor seed inventory does Evogene have, and what are the plans if the current customer does not place a follow-on order? A: Ofer Haviv, President and CEO, stated that while he won't disclose specific inventory amounts, Evogene has a few hundred tons of Casterra seed ready for sale. The company plans to sell these seeds to partners or use them to grow grain through subcontractors, as they have a better understanding of cultivation in certain territories. Initial results from trials in Brazil and Kenya are promising. Q: What steps need to occur before Evogene can announce a castor oil business? A: Ofer Haviv explained that Evogene is currently focused on grain cultivation and selling grain to partners. There is significant demand from oil factories in Africa and Brazil. The main challenge is the cost of growing castor, which Evogene aims to address with its unique variety and growth protocols. Q: The stock is still low. When will it start going up? A: Ofer Haviv mentioned that while the stock market is unpredictable, Evogene is finalizing a new company presentation and website to reflect its strategy. The company plans to announce new collaborations in pharma and agriculture, which should strengthen its value proposition and potentially impact the stock positively. Q: How representative are operating expenses in Q2 2025, and are all cost reductions fully reflected? A: Ofer Haviv confirmed that the third and fourth quarters are expected to show continued declines in expenses across R&D, marketing, and G&A, reflecting the full impact of cost reductions. Q: What was revenue in Q2 '25, and how should we think about peak sales? A: Ofer Haviv noted that Casterra is currently the only activity producing regular sales, primarily from seed sales. The company is in discussions with multiple partners to expand castor oil activities, focusing on reducing cultivation costs to maximize yield versus expenses. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Sign in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Medtronic PLC (MDT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised EPS Guidance
This article first appeared on GuruFocus. Revenue: $8.6 billion, grew 8.4% reported and 4.8% organic. Cardiovascular Growth: 7% growth, driven by nearly 50% growth in cardiac ablation solutions. Neuroscience Growth: 3% growth, with mid-single-digit growth in cranial and spinal technologies. Medsurge Growth: 2% growth, with high single-digit growth in advanced energy. Diabetes Growth: 8% growth, including 11% growth in international markets. Adjusted Gross Margin: 65.1%, down 80 basis points year over year. Adjusted Operating Margin: 23.6%. Adjusted EPS: $1.26, $0.03 above the midpoint of guidance. R&D Investment: Up 7.7%, 100 basis points ahead of revenue growth. Fiscal Year '26 Organic Revenue Growth Guidance: Approximately 5%. Fiscal Year '26 EPS Guidance: Raised to $5.60 to $5.66. Warning! GuruFocus has detected 7 Warning Signs with ODFJF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Medtronic PLC (NYSE:MDT) reported consistent mid-single-digit revenue growth, with EPS exceeding guidance. The cardiovascular segment showed strong performance, with nearly 50% growth in cardiac ablation solutions driven by innovative product rollouts. The company raised its EPS guidance for the full year, reflecting confidence in continued financial acceleration. Medtronic PLC (NYSE:MDT) is poised for growth in the second half of the fiscal year, with several product launches and market expansions planned. The planned separation of the diabetes business is expected to be EPS accretive and improve operating margins, enhancing shareholder value. Negative Points Neuroscience growth was below trend due to specialty therapies, though improvements are expected in subsequent quarters. The Medsurge segment grew only 2%, aligning with expectations but indicating slower growth compared to other segments. The diabetes segment faced challenges in the US market, with growth primarily driven by international sales. Gross margin decreased by 80 basis points year-over-year, impacted by business mix and manufacturing ramp-up costs. Tariffs are expected to have a negative impact of approximately $185 million for fiscal '26, though this is an improvement from previous estimates. Q & A Highlights Q: Can you provide an update on the CAS business and its impact on overall growth? A: Geoff Martha, CEO, explained that the CAS business is accelerating, with 72% growth in the US. The company is confident in its ability to accelerate growth over FY26, with new technologies and a strong pipeline expected to have an outsized impact on US growth. Thierry Pieton, CFO, added that the US growth was impacted by slower growth in certain areas, but expects improvement as new products ramp up. Q: What is the purpose of the new Board committees focused on growth and operations? A: Geoff Martha, CEO, stated that the committees will provide focus and support management, particularly in growth and operational performance. The committees will include new directors with deep medtech experience and will have more frequent interactions with management to drive focus and execution. Q: Is the $2 billion target for annual CAS sales achievable in fiscal '26? A: Geoff Martha, CEO, confirmed that the target of an additional $1 billion on top of the FY25 base is on track. While it might extend into FY27, the company is confident in achieving this near-term goal. Q: How will the new directors and committees impact capital allocation and EPS growth? A: Geoff Martha, CEO, emphasized that the company is entering a new chapter focused on value creation. This includes more M&A, portfolio optimization, and increased investment in growth drivers. The committees will help ensure these strategies are executed effectively. Q: Can you discuss the potential impact of renal denervation on Medtronic's growth profile? A: Geoff Martha, CEO, highlighted that renal denervation (RDN) is a significant growth opportunity, with a massive patient population. The company is investing in market development and expects RDN to be a major driver of growth, potentially becoming one of the largest product categories for Medtronic. Q: What is the status of the diabetes business separation and its impact on growth? A: Thierry Pieton, CFO, confirmed that the separation is on track, with completion expected within 15 months. The diabetes business is entering a strong innovation cycle, and the separation is expected to be a value-creating event for shareholders. Q: How is the Hugo robotic system performing in international markets, and what are the expectations for the US launch? A: Michael Marinaro, EVP, stated that Hugo is performing well in over 30 countries, with significant double-digit growth in current accounts. The system's modular design and partnership approach are key strengths. The company is preparing for the US launch, with FDA approval processes underway. Q: What are the growth prospects for Medtronic's slower-growing businesses? A: Geoff Martha, CEO, noted that several slower-growing businesses have specific growth accelerators, such as new products and market expansions. The company is focused on driving growth across all segments, with organic and inorganic strategies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data